Cargando…

Persistence and viability of SARS-CoV-2 in primary infection and reinfections

Since the beginning of the SARS-CoV-2 epidemic, virus isolation in the infected patient was only possible for a short period of time and it was striking that this occurred constantly and did not provide guidance on the clinical course. This fact led to confusion about the efficacy of some of the dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Galiana, Julián, Ramos, Pilar De Lucas, García-Botella, Alejandra, García-Lledó, Alberto, Gómez-Pavón, Javier, del Castillo, Juan González, Teresa Hernández, Sampelayo, Martín-Delgado, Mari Cruz, Sánchez, Francisco Javier Martín, Martínez-Sellés, Manuel, García, José María Molero, Guillén, Santiago Moreno, Fernando Rodríguez, Artalejo, Cantón, Rafael, Bouza, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790642/
https://www.ncbi.nlm.nih.gov/pubmed/34661382
http://dx.doi.org/10.37201/req/129.2021
_version_ 1784640061527031808
author Ruiz-Galiana, Julián
Ramos, Pilar De Lucas
García-Botella, Alejandra
García-Lledó, Alberto
Gómez-Pavón, Javier
del Castillo, Juan González
Teresa Hernández, Sampelayo
Martín-Delgado, Mari Cruz
Sánchez, Francisco Javier Martín
Martínez-Sellés, Manuel
García, José María Molero
Guillén, Santiago Moreno
Fernando Rodríguez, Artalejo
Cantón, Rafael
Bouza, Emilio
author_facet Ruiz-Galiana, Julián
Ramos, Pilar De Lucas
García-Botella, Alejandra
García-Lledó, Alberto
Gómez-Pavón, Javier
del Castillo, Juan González
Teresa Hernández, Sampelayo
Martín-Delgado, Mari Cruz
Sánchez, Francisco Javier Martín
Martínez-Sellés, Manuel
García, José María Molero
Guillén, Santiago Moreno
Fernando Rodríguez, Artalejo
Cantón, Rafael
Bouza, Emilio
author_sort Ruiz-Galiana, Julián
collection PubMed
description Since the beginning of the SARS-CoV-2 epidemic, virus isolation in the infected patient was only possible for a short period of time and it was striking that this occurred constantly and did not provide guidance on the clinical course. This fact led to confusion about the efficacy of some of the drugs initially used, which seemed to have a high efficiency in viral clearance and proved ineffective in modifying the course of the disease. The immune response also did not prove to be definitive in terms of evolution, although most of the patients with very mild disease had a weak or no antibody response, and the opposite was true for the most severe patients. With whatever the antibody response, few cases have been re-infected after a first infection and generally, those that have, have not reproduced a spectrum of disease similar to the first infection. Among those re-infected, a large number have been asymptomatic or with very few symptoms, others have had a moderate picture and very few have had a poor evolution. Despite this dynamic of rapid viral clearance, laboratory tests were still able to generate positive results in the recovery of genomic sequences and this occurred in patients who were already symptom-free, in others who were still ill and in those who were very seriously ill. There was also no good correlate. For this reason and with the perspective of this year and the half of pandemic, we compiled what the literature leaves us in these aspects and anticipating that, as always in biology, there are cases that jump the limits of the general behavior of the dynamics of infection in general.
format Online
Article
Text
id pubmed-8790642
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-87906422022-02-07 Persistence and viability of SARS-CoV-2 in primary infection and reinfections Ruiz-Galiana, Julián Ramos, Pilar De Lucas García-Botella, Alejandra García-Lledó, Alberto Gómez-Pavón, Javier del Castillo, Juan González Teresa Hernández, Sampelayo Martín-Delgado, Mari Cruz Sánchez, Francisco Javier Martín Martínez-Sellés, Manuel García, José María Molero Guillén, Santiago Moreno Fernando Rodríguez, Artalejo Cantón, Rafael Bouza, Emilio Rev Esp Quimioter Review Since the beginning of the SARS-CoV-2 epidemic, virus isolation in the infected patient was only possible for a short period of time and it was striking that this occurred constantly and did not provide guidance on the clinical course. This fact led to confusion about the efficacy of some of the drugs initially used, which seemed to have a high efficiency in viral clearance and proved ineffective in modifying the course of the disease. The immune response also did not prove to be definitive in terms of evolution, although most of the patients with very mild disease had a weak or no antibody response, and the opposite was true for the most severe patients. With whatever the antibody response, few cases have been re-infected after a first infection and generally, those that have, have not reproduced a spectrum of disease similar to the first infection. Among those re-infected, a large number have been asymptomatic or with very few symptoms, others have had a moderate picture and very few have had a poor evolution. Despite this dynamic of rapid viral clearance, laboratory tests were still able to generate positive results in the recovery of genomic sequences and this occurred in patients who were already symptom-free, in others who were still ill and in those who were very seriously ill. There was also no good correlate. For this reason and with the perspective of this year and the half of pandemic, we compiled what the literature leaves us in these aspects and anticipating that, as always in biology, there are cases that jump the limits of the general behavior of the dynamics of infection in general. Sociedad Española de Quimioterapia 2021-10-18 2022 /pmc/articles/PMC8790642/ /pubmed/34661382 http://dx.doi.org/10.37201/req/129.2021 Text en © The Author 2021 https://creativecommons.org/licenses/by-nc/4.0/Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Review
Ruiz-Galiana, Julián
Ramos, Pilar De Lucas
García-Botella, Alejandra
García-Lledó, Alberto
Gómez-Pavón, Javier
del Castillo, Juan González
Teresa Hernández, Sampelayo
Martín-Delgado, Mari Cruz
Sánchez, Francisco Javier Martín
Martínez-Sellés, Manuel
García, José María Molero
Guillén, Santiago Moreno
Fernando Rodríguez, Artalejo
Cantón, Rafael
Bouza, Emilio
Persistence and viability of SARS-CoV-2 in primary infection and reinfections
title Persistence and viability of SARS-CoV-2 in primary infection and reinfections
title_full Persistence and viability of SARS-CoV-2 in primary infection and reinfections
title_fullStr Persistence and viability of SARS-CoV-2 in primary infection and reinfections
title_full_unstemmed Persistence and viability of SARS-CoV-2 in primary infection and reinfections
title_short Persistence and viability of SARS-CoV-2 in primary infection and reinfections
title_sort persistence and viability of sars-cov-2 in primary infection and reinfections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790642/
https://www.ncbi.nlm.nih.gov/pubmed/34661382
http://dx.doi.org/10.37201/req/129.2021
work_keys_str_mv AT ruizgalianajulian persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT ramospilardelucas persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT garciabotellaalejandra persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT garcialledoalberto persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT gomezpavonjavier persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT delcastillojuangonzalez persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT teresahernandezsampelayo persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT martindelgadomaricruz persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT sanchezfranciscojaviermartin persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT martinezsellesmanuel persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT garciajosemariamolero persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT guillensantiagomoreno persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT fernandorodriguezartalejo persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT cantonrafael persistenceandviabilityofsarscov2inprimaryinfectionandreinfections
AT bouzaemilio persistenceandviabilityofsarscov2inprimaryinfectionandreinfections